Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00368108
First received: August 22, 2006
Last updated: May 13, 2013
Last verified: January 2013
Results First Received: October 23, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Parkinson's Disease
Interventions: Drug: 2 mg perampanel
Drug: 4 mg perampanel
Drug: placebo comparator

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.

Participant Flow:   Overall Study
    Placebo   Perampanel 2mg   Perampanel 4mg
STARTED   251 [1]   251   250 
COMPLETED   187   198   182 
NOT COMPLETED   64   53   68 
Adverse Event                38                26                44 
Abnormal Laboratory Value                0                0                3 
Protocol Violation                5                9                9 
Withdrawal by Subject                9                3                5 
Lack of Efficacy                7                8                5 
Physician Decision                2                0                1 
Not Specified                3                7                1 
[1] One subject had stopped medication prior to notifying staff. Remaining results will have 250.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
Total Total of all reporting groups

Baseline Measures
   Placebo   Perampanel 2mg   Perampanel 4mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 250   251   250   751 
Age, Customized 
[Units: Participants]
       
<65 years   149   144   147   440 
≥ 65 years   101   107   103   311 
Gender 
[Units: Participants]
       
Female   86   87   86   259 
Male   164   164   164   492 
Race/Ethnicity, Customized 
[Units: Participants]
       
White   233   239   240   712 
Black   4   2   1   7 
Asian   5   4   1   10 
Other   8   6   8   22 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data)   [ Time Frame: Baseline and Week 20 ]

2.  Secondary:   Mean Change From Baseline in Scale UPDRS Part II (ADL) Score in Total Daily OFF Time to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]

3.  Secondary:   Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]

4.  Secondary:   Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame From the time the subject signed the informed consent form to 30 days after the last dose of the study drug.
Additional Description Adverse events were assessed at clinical visits based on the subject's diary, vitals, weight, physical examination, neurological exam, and laboratory evaluations.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.

Serious Adverse Events
    Placebo   Perampanel 2mg   Perampanel 4mg
Total, Serious Adverse Events       
# participants affected / at risk   22/250 (8.80%)   12/251 (4.78%)   18/250 (7.20%) 
Blood and lymphatic system disorders       
Anaemia † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Cardiac disorders       
Atrial flutter † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Coronary artery disease † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Myocardial infarction † 1       
# participants affected / at risk   2/250 (0.80%)   1/251 (0.40%)   0/250 (0.00%) 
Myocardial ischaemia † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Angina Pectoris † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Cardio-Respiratory arrest † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Coronary artery occlusion † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Gastrointestinal disorders       
Constipation † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Large intestine perforation † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Oesophageal stenosis † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Small intestinal obstruction † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Crohn's disease † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Gastrointestinal haemorrhage † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Rectal haemorrhage † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
General disorders       
Non-cardiac chest pain † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   1/250 (0.40%) 
Chest pain † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Pain † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Infections and infestations       
Pneumonia † 1       
# participants affected / at risk   2/250 (0.80%)   0/251 (0.00%)   2/250 (0.80%) 
Cellulitis † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Urinary tract infection † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Injury, poisoning and procedural complications       
Fall † 1       
# participants affected / at risk   1/250 (0.40%)   1/251 (0.40%)   1/250 (0.40%) 
Femur fracture † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   1/250 (0.40%) 
Hip fracture † 1       
# participants affected / at risk   2/250 (0.80%)   0/251 (0.00%)   1/250 (0.40%) 
Wrist fracture † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Joint dislocation † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Stress fracture † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Metabolism and nutrition disorders       
Dehydration † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Musculoskeletal and connective tissue disorders       
Pain in extremity † 1       
# participants affected / at risk   1/250 (0.40%)   1/251 (0.40%)   0/250 (0.00%) 
Osteoarthritis † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)       
Melanoma recurrent † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Bile duct cancer † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Prostate cancer † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Nervous system disorders       
Syncope † 1       
# participants affected / at risk   1/250 (0.40%)   1/251 (0.40%)   1/250 (0.40%) 
Cerebrovascular accident † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Memory Impairment † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Myasthenia gravis † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
ON and OFF phenomenon † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Quadriparesis † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Tremor † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Reversible ischaemic neurological deficit † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Tonic convulsion † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Psychiatric disorders       
Confusional state † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Hallucination † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Suicide attempt † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Delirium † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Hallucination, visual † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Major depression † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Renal and urinary disorders       
Nephrolithiasis † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Micturition urgency † 1       
# participants affected / at risk   1/250 (0.40%)   0/251 (0.00%)   0/250 (0.00%) 
Respiratory, thoracic and mediastinal disorders       
Dyspnoea † 1       
# participants affected / at risk   0/250 (0.00%)   0/251 (0.00%)   1/250 (0.40%) 
Surgical and medical procedures       
Hospitalization † 1       
# participants affected / at risk   0/250 (0.00%)   1/251 (0.40%)   0/250 (0.00%) 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA V. 10.1




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information